Suppr超能文献

相似文献

4
Pediatric combined living donor liver and kidney transplantation for primary hyperoxaluria type 2.
Am J Transplant. 2023 Oct;23(10):1622-1625. doi: 10.1016/j.ajt.2023.05.006. Epub 2023 May 13.
5
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13.
7
Identification of a novel AGXT gene mutation in primary hyperoxaluria after kidney transplantation failure.
Transpl Immunol. 2016 Nov;39:60-65. doi: 10.1016/j.trim.2016.08.008. Epub 2016 Aug 25.
8
Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children.
Nephrol Dial Transplant. 2001 Feb;16(2):348-54. doi: 10.1093/ndt/16.2.348.
9
Combined liver-kidney transplantation in primary hyperoxaluria type 1.
Eur J Pediatr. 1999 Dec;158 Suppl 2:S75-80. doi: 10.1007/pl00014327.

引用本文的文献

3
The efficacy and safety of RNA interference for the treatment of primary hyperoxaluria: a systematic review and meta-analysis.
Clin Kidney J. 2024 Nov 29;18(4):sfae383. doi: 10.1093/ckj/sfae383. eCollection 2025 Apr.
5
Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.
Kidney Dis (Basel). 2024 Jun 17;10(4):313-326. doi: 10.1159/000539516. eCollection 2024 Aug.
6
Diverse retinal-kidney phenotypes associated with homozygous whole-gene deletions in patients with kidney failure.
J Rare Dis (Berlin). 2024;3(1):7. doi: 10.1007/s44162-024-00031-4. Epub 2024 Mar 1.
7
Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1.
Kidney Int Rep. 2023 Oct 6;9(1):114-133. doi: 10.1016/j.ekir.2023.10.004. eCollection 2024 Jan.
8
Four novel variants identified in primary hyperoxaluria and genotypic and phenotypic analysis in 21 Chinese patients.
Front Genet. 2023 Apr 17;14:1124745. doi: 10.3389/fgene.2023.1124745. eCollection 2023.
9
Lumasiran for primary hyperoxaluria type 1: What we have learned?
Front Pediatr. 2023 Jan 10;10:1052625. doi: 10.3389/fped.2022.1052625. eCollection 2022.
10
[Nephrolithiasis and nephrocalcinosis in children and adolescents].
Urologie. 2022 Oct;61(10):1099-1109. doi: 10.1007/s00120-022-01888-3. Epub 2022 Jul 8.

本文引用的文献

1
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712.
2
Lumasiran: First Approval.
Drugs. 2021 Feb;81(2):277-282. doi: 10.1007/s40265-020-01463-0.
4
Primary hiperoxaluria diagnosed after kidney transplantation: report of 2 cases and literature review.
J Bras Nefrol. 2017 Oct-Dec;39(4):462-466. doi: 10.5935/0101-2800.20170081.
5
Identification of a novel AGXT gene mutation in primary hyperoxaluria after kidney transplantation failure.
Transpl Immunol. 2016 Nov;39:60-65. doi: 10.1016/j.trim.2016.08.008. Epub 2016 Aug 25.
6
Acute oxalate nephropathy following kidney transplantation: Report of three cases.
J Res Med Sci. 2015 Aug;20(8):818-23. doi: 10.4103/1735-1995.168408.
8
Primary hyperoxaluria.
N Engl J Med. 2013 Aug 15;369(7):649-58. doi: 10.1056/NEJMra1301564.
9
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment.
Nephrol Dial Transplant. 2012 May;27(5):1729-36. doi: 10.1093/ndt/gfs078.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验